In conclusion, the current evidence for tofersen in SOD1 ALS demonstrates promising results, with significant reductions in CSF SOD1 concentrations and plasma NfL levels, along with a slowing of disease progression as measured by ALSFRS-R. Here, NEFL is linked to amyotrophic lateral sclerosis.